67226-78-2

Basic information

• Product Name: Ethyl [(tert-Butyldimethylsilyl)oxy]acetate
• Synonyms: 2-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-acetic Acid Ethyl Este;Ethyl [(tert-Butyldimethylsilyl)oxy]acetate;2-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-acetic Acid Ethyl Ester;ethyl 2-(tert-butyldiMethylsilyloxy)acetate
• CAS NO: 67226-78-2
• Molecular Formula: C₁₀H₂₂O₃Si
• Molecular Weight: 218.37
• Product Categories: All Aliphatics;Aliphatics
• Mol File: 67226-78-2.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 40-420C
• Flash Point: 70.2°C
• Appearance: /
• Density: 0.912g/cm³
• Vapor Pressure: 0.145mmHg at 25°C
• Refractive Index: 1.42
• Storage Temp.: Refrigerator
• Solubility: Acetone, Chloroform, Dichloromethane, Ethyl Acetate, Methanol
• CAS DataBase Reference: Ethyl [(tert-Butyldimethylsilyl)oxy]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl [(tert-Butyldimethylsilyl)oxy]acetate(67226-78-2)
• EPA Substance Registry System: Ethyl [(tert-Butyldimethylsilyl)oxy]acetate(67226-78-2)

Safety Data

• Hazardous Substances Data: 67226-78-2(Hazardous Substances Data)

Usage

Chemical Properties

Colorless Oil

Uses

Ethyl [(tert-Butyldimethylsilyl)oxy]acetate (cas# 67226-78-2) is a compound useful in organic synthesis.

InChI:InChI=1/C10H22O3Si/c1-7-12-9(11)8-13-14(5,6)10(2,3)4/h7-8H2,1-6H3

Upstream product

• 623-50-7 ethyl 2-hydroxyacetate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 64-17-5 ethanol 
• 67226-76-0 (tert-butyldimethylsiloxy) acetic acid tert-butyldimethylsilyl ester 

Downstream Products

• 105459-05-0 {[tert-butyl(dimethyl)silyl]oxy}acetic acid 
• 1414570-97-0 (5-amino-1-phenyl-1H-pyrazol-3-yl)methanol 
• 1453851-61-0 (R)-2-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-fluorophenyl)ethyl methanesulfonate 
• 1453851-99-4 (R)-2-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-fluorophenyl)ethanol 
• 1312718-88-9 2-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-fluorophenyl)ethanone 
• 163089-34-7 N-methoxy-N-methyl-2-(1,1,2,2-tetramethyl-1-silapropoxy)acetamide 
• 1453852-96-4 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-fluorophenyl)ethyl)-4-(2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453852-94-2 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-fluorophenyl)ethyl)-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1453852-92-0 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(3-chloro-4-fluorophenyl)ethyl)-4-(2-(methylthio)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1312719-22-4 (S)-2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethanamine 
• 1395078-44-0 (S)-2-(2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)isoindoline-1,3-dione 
• 1395078-43-9 (R)-2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethanol 
• 1312718-89-0 2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethanone 
• 198218-59-6 S-ethyl (2R,3S,4E)-2-(tert-butyldimethylsiloxy)-3-hydroxy-5-phenyl-4-pentenethioate 

Relevant articles and documents

Hydrophilic azaspiroalkenes as robust bioorthogonal reporters

Two hydrophilic spiroalkenes, azaspiro[2.3]hex-1-ene and azaspiro[2.4]hept-1-ene, were designed and synthesized. Compared to the previously reported spiro[2.3]hex-1-ene, the azaspiroalkenes exhibited greater water solubility and reactivity as dipolarophiles in the photoinduced tetrazole-alkene cycloaddition reaction. In addition, an azaspiro[2.3]hex-1-ene-containing amino acid, AsphK, was found to be charged by an engineered pyrrolysyl-tRNA synthetase into proteins via amber codon suppression in E. coli as well as in mammalian cells.

Pyrido[1,2-a]pyrimidone analogs as PI3K inhibitors

The present invention discloses a class of pyrido[1,2-a]pyrimidone analogs as PI3K inhibitors, and particularly relates to a compound represented by a formula (I) or a pharmaceutically acceptable salt thereof. The formula (I) is defined in the specification.

THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.